黄连素联合阿托伐他汀对急性脑梗死患者治疗作用的研究

目的：探讨黄连素联合阿托伐他汀对急性脑梗死（ACI）患者血清炎症因子（MIF、IL-6、CRP）水平及短期临床预后的作用。方法：选择120例ACI患者，随机分为联合组（n=60）和阿托伐他汀组（n=60）。两组均给予ACI常规治疗。联合组给予黄连素（300 mg tid）+阿托伐他汀（40 mg qd），阿托伐他汀组仅给予阿托伐他汀（40 mg qd）。测定所有患者的血清MIF、IL-6、CRP水平（入院第1、14天）及进行神经功能缺损评分（入院第1、14、90天）。结果：入院第1天及第14天，两组患者血清MIF、IL-6、CRP水平与NIHSS评分呈正相关（P<0.05）；入院第1天，两组间患者的MIF、IL-6、CRP水平及NIHSS评分比较均无统计学意义（P>0.05）；入院第14天较第1天，两组患者的血清MIF、IL-6、CRP水平及NIHSS评分均显著降低（P<0.05）；入院第14天，联合组较阿托伐他汀组血清MIF、IL-6、CRP水平及NIHSS评分显著降低（P<0.05）；随访第90天，联合组较阿托伐他汀组mRS评分显著偏低（P<0.05），短期预后良好率显著偏高（P<0.05）。结论：对急性脑梗死的治疗，黄连素联合阿托伐他汀治疗可显著降低ACI急性期血清炎症因子MIF、IL-6、CRP水平，并显著促进神经功能恢复，改善短期预后。

Effect of Berberine Combined with Atorvastatin on Patients with Acute Cerebral Infarction

Objective: To investigate the effect of berberine combined with atorvastatin on serum in-flammatory factors and short-term prognosis in patients with acute cerebral infarction (ACI). Methods: A total of 120 patients with ACI were recruited and randomly divided into 2 groups: combined group (n=60) and atorvastatin group (n=60). They all received the basic treatment of ACI. Combined group received berberine (300 mg tid) and atorvastatin (40 mg qd). Atorvastatin group received atorvastatin (40 mg qd). The levels of serum MIF, IL-6 and CRP (day 1 and day 14) and the nerve function defect grades (day 1, day 14 and day 90) were measured. Results: There was positive correlation of serum MIF, IL-6 and CRP with NIHSS scores on day 1 and day 14 (P<0.05). The levels of serum MIF, IL-6and CRP and NIHSS scores were not significantly different between the combined group and the atorvastatin group on day 1 (P>0.05). The levels of serum MIF, IL-6 and CRP and NIHSS scores of the two groups on day 14 were significantly lower than those on day 1 (P<0.05). The levels of serum MIF, IL-6 and CRP and NIHSS scores of the combined group were significantly lower than those of the atorvastatin group on day 14 (P<0.05). The mRS scores of the combined group were significantly lower than those of the atorvastatin group on day 90 (P<0.05), with significantly higher rate of short-term favorable prognosis (P<0.05). Conclusions: Combined berberine with atorvastatin can significantly down-regulate the levels of serum MIF, IL-6 and CRP and improve neurological impairment and the short-term favorable prognosis in patients with acute cerebral in-farction.